First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Neogen: the story is balanced — Food safety incident headlines (E.coli outbreaks, listeria recalls) that drive testing demand and regulatory scrutiny
★ Analysts see FY2027 revenue reaching $880M — +1.1% growth in a single year.
What Moves the Stock
1Food safety incident headlines (E.coli outbreaks, listeria recalls) that drive testing demand and regulatory scrutiny
2Agricultural commodity prices and livestock herd sizes affecting animal safety product demand and genomic testing volumes
3New product launches and regulatory approvals for rapid pathogen detection platforms
4Acquisition announcements or integration progress from consolidation in fragmented diagnostics market
5Margin expansion trajectory as company scales past breakeven on operating expenses
6Food Safety diagnostics (estimated 50-55%): Test kits and systems for pathogen detection, allergen testing, mycotoxin screening, and food quality indicators sold to food processors, restaurants, and retail chains
7Animal Safety products (estimated 35-40%): Veterinary instruments, pharmaceuticals, disinfectants, rodenticides, and genomic testing services for livestock producers and companion animal veterinarians
8Genomics services (estimated 5-10%): DNA testing for livestock breeding optimization, primarily serving beef and dairy cattle producers seeking genetic improvement
momentum - The 71.2% three-month and 102.4% six-month returns indicate strong momentum investor interest despite weak fundamentals…
Rising interest rates create moderate headwinds through higher financing costs on the company's debt (0.38 D/E ratio) and potential…
Watch on earnings: Corn and soybean futures prices (ZCUSX, ZSUSX) as proxies for livestock feed costs and producer profitability affecting animal safety demand, Live cattle and lean hog futures (LEUSX, HEUSX) indicating livestock production cycles and genomic testing volumes, Food safety recall announcements and FDA enforcement actions driving testing demand urgency.
One Sentence Summary:
Neogen: the story is balanced — food safety incident headlines (e.coli outbreaks, listeria recalls) that drive testing demand and regulatory scrutiny.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.